Journal: International Journal of Molecular Sciences

Article Title: APP Knock-In Mice Produce E22P-Aβ Exhibiting an Alzheimer’s Disease-like Phenotype with Dysregulation of Hypoxia-Inducible Factor Expression

doi: 10.3390/ijms232113259

Figure Lengend Snippet: Alzheimer’s disease (AD)-related histological changes in the brain of APP NL-P-F/NL-P-F mice. ( A ) The Aβ plaque deposition was detected by 82E1 in the hippocampal CA1, DG, and cortex of APP NL-P-F/NL-P-F mice from three to twelve months. The scale bar indicates 1 mm in representative coronal sections and 100 μm in each region). ( B ) The Aβ plaque area in the hippocampal CA1, DG, and the cortex of APP NL-P-F/NL-P-F mice from three to twelve months. WT ( n = 6) and NLPF ( n = 7–9). ( C , D ) Representative ( C ) fluorescent and ( D ) confocal images of tau phosphorylation were detected by PHF-1 (Ser396/Ser404) in the hippocampal CA1, CA3, and DG after twelve months. The scale bar indicates ( C ) 1 mm (50 μm in enlarged images) and ( D ) 50 μm (25 μm in enlarged images of CA1 area). ( E ) After twelve months, the phosphorylated tau-positive area (% of total area) in the hippocampal CA1, CA3, and DG. WT and NLPF ( n = 6). ( F , G ) After twelve months, representative ( F ) fluorescent and ( G ) confocal images of NeuN in the hippocampal CA1 and CA3. The scale bar indicates ( F ) 250 μm (50 μm in enlarged images) and ( G ) 50 μm. ( H ) After twelve months, the number of NeuN-positive neurons in the hippocampal CA1 and CA3. WT ( n = 17 slices/6 mice), NLPF ( n = 13 slices/6 mice). The values indicate the mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001, compared with age-matched WT.

Article Snippet: Mouse Anti-Human Amyloid β antibody (82E1) , 1:1000 , Immuno-Biological Laboratories, Gunma, Japan , 10323.

Techniques:

Journal: International Journal of Molecular Sciences

Article Title: APP Knock-In Mice Produce E22P-Aβ Exhibiting an Alzheimer’s Disease-like Phenotype with Dysregulation of Hypoxia-Inducible Factor Expression

doi: 10.3390/ijms232113259

Figure Lengend Snippet: Primary antibodies used for immunohistochemistry (IHC).

Article Snippet: Mouse Anti-Human Amyloid β antibody (82E1) , 1:1000 , Immuno-Biological Laboratories, Gunma, Japan , 10323.

Techniques: Immunohistochemistry

Journal: Frontiers in Cellular Neuroscience

Article Title: Alzheimer’s disease like neuropathology in Down syndrome cortical organoids

doi: 10.3389/fncel.2022.1050432

Figure Lengend Snippet: List of reagents and chemicals.

Article Snippet: Amyloid beta (N) (82E1) anti-human mouse IGG , 10323 , IBL-America.

Techniques: Staining, Protease Inhibitor, Imaging, Enzyme-linked Immunosorbent Assay

Journal: Frontiers in Cellular Neuroscience

Article Title: Alzheimer’s disease like neuropathology in Down syndrome cortical organoids

doi: 10.3389/fncel.2022.1050432

Figure Lengend Snippet: Abnormal Aß accumulation in DS iPSCs-derived cortical organoids. (A) A representative Aß immunostaining in 12 weeks DS and isogenic control organoids with two different antibodies D54D2 (Aß37-42, green) and 82E1 (Aß40-42, red). (B) Immunohistochemical analysis of Aß antibodies D54D2 and 82E1 revealed a significantly increased Aß immunoreactivity in DS organoids ( n = 10–11, p < 0.01). (C) A representative Aß plaque staining in DS and control organoids using Amylo-Glo. (D) Immunohistochemical analysis of Amylo-Glo revealed a significantly increased amyloid plaque load in DS organoids ( n = 8, p < 0.05). (E) Aß40 and Aß42 in the soluble and insoluble fractions of 8 weeks and 12 weeks DS and control organoids were quantified using Elisa and the ratio of Aß42/Aß40 was significantly increased in the insoluble fractions of 12 weeks DS organoids ( n = 10–11, p < 0.05). * p < 0.05, and ** p < 0.01 vs. Control.

Article Snippet: Amyloid beta (N) (82E1) anti-human mouse IGG , 10323 , IBL-America.

Techniques: Derivative Assay, Immunostaining, Control, Immunohistochemical staining, Staining, Enzyme-linked Immunosorbent Assay

Journal: Neuropathology and applied neurobiology

Article Title: N-terminal heterogeneity of parenchymal and vascular amyloid-β deposits in Alzheimer’s disease

doi: 10.1111/nan.12637

Figure Lengend Snippet: Assessment of antibody selectivity by capillary isoelectric focusing immunoassay. Synthetic amyloid-β (Aβ) peptides with different N-termini were separated by isoelectric focusing in microcapillaries, immobilized by a photochemical reaction and probed with the indicated primary antibodies. Chemiluminescence detection was achieved with peroxidase-labelled anti mouse antibodies (80C2, 82E1). In case of 24311, 18H6 and the humanized biosimilar antibodies Bapineuzumab and Crenezumab, biotinylated anti-rabbit, anti-mouse or anti-human IgG plus peroxidase-conjugated streptavidin were employed. For each one of the indicated primary antibodies, a mixture of Aβ 1–40, Aβ 2–40 and Aβ 5–40 (electropherogram A ), a mixture of Aβ pE3–40 , Aβ 4–40 and Aβ 11–40 ( B ), Aβ 3–40 ( C ) and N-terminally elongated Aβ −3–40 (APP669–711) ( D ) were assessed. To facilitate the evaluation of the selectivity for specific N-terminal Aβ variants, the electropherograms were scaled for each primary antibody according to the maximum signal that was observed. Note that the signals obtained with the humanized biosimilar antibodies Bapineuzumab and Crenezumab were substantially higher than with the mouse monoclonals. Presumably, in these two cases the combination of a biotinylated anti human antibody and peroxidase-conjugated streptavidin provided highly efficient signal amplification.

Article Snippet: After three washing steps with PBS-T, biotinylated goat anti-mouse IgG (1:3000 in PBS-T; Life Technologies, Carlsbad, CA, USA) for 82E1 and biotinylated goat anti-human IgG (DAKO, Glostrup, Denmark, 1:3000) for Bapineuzumab, followed by streptavidin-HRP, were employed as secondary reagents.

Techniques: Amplification